Scancell Share Discussion Threads

[marcusl2] 28/7/2023 07:32

(About 13 rows down)

I presume she will be telling people about Modi-1 working well in combination with CPIs and excellent Scib-1 plus doublet data. Hopefully iScib-1 started by then.

Prof Lindy Durrant, Joint Chief Executive Officer and Cso, Scancell Ltd

[marcusl2] 28/7/2023 07:31

(About 13 rows down)

I presume she will be telling people about Modi-1 working well in combination with CPIs and excellent Scib-1 plus doublet data. Hopefully iScib-1 started by then.

Prof Lindy Durrant, Joint Chief Executive Officer and Cso, Scancell Ltd

[ivyspivey] 28/7/2023 06:41

Morning Marcus thanks for speaker link.
I downloaded the agenda but could not see LD slot in Cancer Vax so have I just missed her on agenda or do you know what she is talking about.
See Ira Mellman is talking

[marcusl2] 27/7/2023 20:46

World Vaccine Congress Europe 2023 | 16 - 19 October 2023


The region's largest event dedicated to vaccine business, science and technology development.

[1knocker] 27/7/2023 19:16

No one needs to be a 'technician', let alone a chartless chartist in order to be proved 'entirely accurate' when predicting that an share price could go up or might go down.

To be fair though, I do accept that such a prediction does have the merit of accuracy, though its usefulness is more difficult to discern. You can't make money on a two way bet on a two horse race though. But perhaps you count 'sideways movement' as a third horse in the race? Do remember that you can't make money on sideways movement either, whether you are short or long.

I do sympathise though. the RMM and Mode Global Holdings debacles will still be fresh in your memory, leading you to the [entirely accurate] conclusion that a two way bet on a two horse race, though pointless, is at least better than backing a faller.

[volsung] 27/7/2023 19:06

It was 1952
I was a young District Commissioner in Bechuanaland
Goodness it was hot!
Ngutu, my trusty servant had just located a bull elephant which had been rampaging through the local villages
I shot the buggar, the elephant, not Ngutu.
They were different times

[2tyke] 27/7/2023 19:05

Loggy...probably best to love tinnies if one follows LUFC...lol

[thelogman] 27/7/2023 19:03

TINNIES are the future, get some shop lifting done to rebel against price increases 😜😜😜👍

[thelogman] 27/7/2023 19:01

2tyke, you may be right I fell in love with my tinnies and still in denial that I can do without them😂

[2tyke] 27/7/2023 18:50

That's right Ivy.
The odds thing is that the scientists and fundamentalists have over a decade of proof that their premise on stock prices is INVARIABLY WRONG.
They still maintain that the market is actually wrong. Thus, they demonstrate ZERO intellectual honesty.
Meanwhile...a technician has come onto the bb and been proved entirely accurate...in advance of the price moves.
Like you say....why wouldn't anyone want to know more ?
The answer is a complex mix of 'falling in love' and 'denial'.

[ivyspivey] 27/7/2023 16:39

2tyke
Appreciate the TA and really don’t see why anyone would not want additional info to help them make balanced decisions but each to their own.
You don’t have to accept any others pov or info but if you have a closed mind to any other input then likely your decision making will be flawed

[2tyke] 27/7/2023 15:32

Yeah right ......so are you for £8....lol

[inanaco] 27/7/2023 15:29

missing a time period

[2tyke] 27/7/2023 14:11

So looking at the SCLP technical chart. The EW pattern indicates a bottom should be very near and minimum expectations have already been met.
The current low was at 8.7p, and that was followed by a rise to 11.2p.
'IF' this was a small degree first wave up, the 8.7p should hold. Today's lowest trade was 9.05p. There are however, no signs currently of 'positive deviation' in the price data, which is usually the case at a price bottom.
This may be rectified by one more low in price.
There is also a gap in the daily chart at 7.1p which may need to be filled.
So likely the final price bottom will be somewhere between 7p and 9p. This should be accompanied by positive divergence in the price data, indicating a change in trend.

[golcheja] 27/7/2023 13:43

Marcus keeps posting his old news and share on target to reach 5p. Too much focus on science and too little on the commercial aspects, as big mama says money talks and the prof Share option walks.

[2tyke] 27/7/2023 13:41

That's right Panama ..lol
But finally, finally, some negativity starting to appear on the happy clappy LSE bb.
Just what one would expect if a share price 'bottom' is in sight !
Always the same in the market....did I mention to it's a place of irony....and complete contradiction ??

[panama7] 27/7/2023 12:40

Inane, when you were posting that this will go to £ 8 a share was it a typo, did you mean 8p a share. Looks like you will have to rely on your car park for your pension but with the war against cars not sure that was a very shrewd investment either.

[the real lozan] 27/7/2023 10:55

My location -
I just wish some of you could see what I am looking at right now.

[marcusl2] 26/7/2023 13:37

SCIB1 – Phase 1/2 reduced recurrence and turned cancer into a
chronic disease
88% of patients remained disease-free for 5+ years

[marcusl2] 26/7/2023 13:30

Development partners Merck & Co. and Moderna announced Wednesday the initiation of a Phase III clinical trial evaluating the investigational mRNA cancer vaccine V940/mRNA-4157 in combination with Keytruda (pembrolizumab) for the adjuvant treatment of patients with resected high risk (Stage IIB-IV) melanoma.

The study will compare safety and efficacy of the combination versus Keytruda monotherapy and will enroll approximately 1,089 patients at more than 165 sites in over 25 countries. The primary endpoint is recurrence-free survival (RFS) and secondary endpoints include distant metastasis-free survival (DMFS) and overall survival (OS).

Updated findings from a Phase IIb study were presented last month at the American Society of Clinical Oncology (ASCO) meeting, showing that the combination of V940 and Keytruda reduced the risk of distant metastasis or death by 65%, compared to Keytruda alone, in patients with high-risk melanoma.

“As we continue our efforts to advance novel treatment options for patients with high-risk Stage IIB-IV melanoma, the initiation of the V940-001 Phase 3 trial represents an important step forward in these efforts and our study of individualized neoantigen therapy,” said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development at Merck.

Merck and Moderna also plan to expand the development programme for V940 in combination with Keytruda to additional tumour types, including non-small cell lung cancer (NSCLC).

[cleanerworldwehope] 26/7/2023 11:09

mr Tyke nothing to do with football ! nor Scancell
hxxps://www.investopedia.com/terms/s/seagull-option.asp

[inanaco] 26/7/2023 10:20

still waiting for an actual prediction